sobi-003
Recombinant proteinexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 19, 2018 (NCT03423186)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- N-sulphoglucosamine sulphohydrolaseSupplementation
SGSH supplementation
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- NCATSZS87P77DQC ↗
- ChEMBLCHEMBL4298107 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03811028 | Phase 1/Phase 2 (Phase 2) | Jan 23, 2019 | Children´s Hospital and Research Center, Oakland, Swedish Orphan Biovitrum |
| NCT03423186 | Phase 1/Phase 2 (Phase 2) | Jun 19, 2018 | Swedish Orphan Biovitrum, University of California, San Francisco |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Swedish Orphan Biovitrum | For profit | 2 | 2 | 1 | 2018 |
| Children´s Hospital and Research Center, Oakland | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2018 |
3 organizations
Page 1 / 1